

## HEAD & NECK CANCER

### Neo-Adjuvant

**UCI 16-72** Randomized Double-Blind Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard of Care Chemoradiotherapy in the Front-Line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (**Ejadi**)

**UCI 17-33** A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy with the IRX-2 Regimen in Patients with Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity (**Ejadi**)


**\*\*SUSPENDED\*\* NRG-HN001** Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) (**Ejadi**)

### Metastatic

**\*\*SUSPENDED\*\* UCI 16-50** Phase 1b/2, Open-Label, Multicenter Study Assessing the Safety, Tolerability, Pharmacokinetics & Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Pts With Advanced Solid Malignancies & Subsequently Comparing AZD9150 & AZD5069 Both as Monotherapy & in Combination With MEDI4736 as Second Line Treatment in Pts With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (**Nelson**)

**RTOG-0920** Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer (**Daroui**)

**UCI 17-57\*\*** A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Who Have Failed pembrolizumab Monotherapy or Who Have Failed to Demonstrate an Objective Response After 3 Months of Pembrolizumab Monotherapy (**Nangia**)



**Correlative**

**UCI 14-25** Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (**Nelson**)

**UCI 16-01** (PAINT Cancer)-Pathway Analyses for Individualized Network Therapeutics for Cancer (**Nelson**)

**Multiple Disease Sites**

**UCI 13-49** Open-Label Dose-Escalation Trial to Evaluate the Safety, PK, and PD of Daily Oral MGCD265 Administered Without Interruption to Subjects with Advanced Malignancies (**Ou**)

**UCI 16-96** A Phase I Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (**Ou**)

**ECOG-EAY131** Molecular Analysis for Therapy Choice (MATCH) (Larynx, Lip, Oral Cavity & Pharynx) (**Bota**)

**SWOG S1609** DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (**Bota**)

**UCI 17-50\*\*** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (**Ou**)

**UCI 17-58\*\*** Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas (**Pinter-Brown**)